CTOs on the Move

Promab Biotechnologies

www.promab.com

 
Promab Biotechnologies is a Albany, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million
  • www.promab.com
  • 715 Johnson St
    Albany, CA USA 94706
  • Phone: 510.860.4615

Executives

Name Title Contact Details

Similar Companies

Revvity

At Revvity, “impossible” is inspiration, and ""can`t be done"" is a call to action. Revvity provides health science solutions, technologies, expertise and services that deliver complete workflows from discovery to development, and diagnosis to cure. Revvity is revolutionizing what`s possible in healthcare, with specialized focus areas in translational multi-omics technologies, biomarker identification, imaging, prediction, screening, detection and diagnosis, informatics and more. With more than $3 billion in revenue and over 11,000 employees, Revvity serves customers across pharmaceutical and biotech, diagnostic labs, academia and governments. It is part of the S&P 500 index and has customers in more than 190 countries.

MicroGEM

At MicroGEM, we are transforming the landscape of DNA and RNA extraction. Come see how our single-tube extraction workflows can work for you!

ALCON LABORATORIES INC

ALCON LABORATORIES INC is a Fort Worth, TX-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Calithera

Calithera is discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Calithera Biosciences is a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer. Tumor metabolism and tumor immunology have emerged as promising new fields for cancer drug discovery, and recent clinical successes with therapeutic agents in each field have demonstrated the potential to create fundamentally new therapies for cancer patients. Our lead product candidate in tumor metabolism, CB-839, is an internally discovered, first-in-class inhibitor of glutaminase, a critical enzyme in tumor metabolism. We are currently evaluating CB-839 in three Phase 1 clinical trials in solid and hematological tumors. In tumor immunology, our lead preclinical program is directed at developing inhibitors of the enzyme arginase and may provide a first-in-class therapeutic agent for this novel target. Our ongoing research efforts are focused on discovering additional product candidates against novel tumor metabolism and immunology targets.

Juneau Biosciences

Juneau Biosciences is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.